CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HLCM051Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug105 Abivertinib Wiki 1.00
drug2319 Standard of Care Wiki 0.20

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis

The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.

NCT03807804 Respiratory Distress Syndrome, Adult Biological: HLCM051
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Description: VFD for 28 days after administration of the investigational product

Measure: Ventilator-free days (VFD)(ARDS caused by pneumonia cohort)

Time: 28 days after administration of the investigational product

Description: The number and rate of adverse events

Measure: Adverse events(ARDS caused by COVID-19 cohort)

Time: From informed consent to 180 days after administration of the investigational product

Description: Change from baseline in systolic blood pressure(mmHg)

Measure: Change from baseline in systolic blood pressure(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in diastolic blood pressure(mmHg)

Measure: Change from baseline in diastolic blood pressure(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in pulse rate(beats/min)

Measure: Change from baseline in pulse rate(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in respiration(breath/min)

Measure: Change from baseline in respiration(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in oxygen saturation(%)

Measure: Change from baseline in oxygen saturation(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in body temperature(C)

Measure: Change from baseline in body temperature(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in red blood cell count(/uL)

Measure: Change from baseline in red blood cell count(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in hemoglobin(g/dL)

Measure: Change from baseline in hemoglobin(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in hematocrit(%)

Measure: Change from baseline in hematocrit(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in leukocyte count(/uL)

Measure: Change from baseline in leukocyte count(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in neutrophils(%)

Measure: Change from baseline in neutrophils(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in eosinophils(%)

Measure: Change from baseline in eosinophils(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in basophils(%)

Measure: Change from baseline in basophils(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in lymphocytes(%)

Measure: Change from baseline in lymphocytes(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in monocytes(%)

Measure: Change from baseline in monocytes(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in platelet count(/uL)

Measure: Change from baseline in platelet count(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in asparate aminotransferase(AST)(IU/L)

Measure: Change from baseline in asparate aminotransferase(AST)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in alanine aminotransferase(ALT)(IU/L)

Measure: Change from baseline in alanine aminotransferase(ALT)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in alkaline phosphatase(ALP)(IU/L)

Measure: Change from baseline in alkaline phosphatase(ALP)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in total bilirubin(mg/dL)

Measure: Change from baseline in total bilirubin(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in blood urea nitrogen(BUN)(mg/dL)

Measure: Change from baseline in blood urea nitrogen(BUN)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in creatinine(mg/dL)

Measure: Change from baseline in creatinine(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in sodium(Na)(mmol/L)

Measure: Change from baseline in sodium(Na)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in potassium(K)(mmol/L)

Measure: Change from baseline in potassium(K)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in chloride(Cl)(mmol/L)

Measure: Change from baseline in chloride(Cl)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in calcium(Ca)(mg/dL)

Measure: Change from baseline in calcium(Ca)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in blood sugar(mg/dL)

Measure: Change from baseline in blood sugar(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in urinary protein(- to >= 4+)

Measure: Change from baseline in urinary protein(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in urinary sugar(- to >= 4+)

Measure: Change from baseline in urinary sugar(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in uric blood(- to >= 4+)

Measure: Change from baseline in uric blood(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in urinary sediment(RBC)(/HPF)

Measure: Change from baseline in urinary sediment(RBC)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in urinary sediment(WBC)(/HPF)

Measure: Change from baseline in urinary sediment(WBC)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product

Description: Change from baseline in urinary sediment(Other)(/HPF)

Measure: Change from baseline in urinary sediment(Other)(ARDS caused by COVID-19 cohort)

Time: From screening to 180 days after administration of the investigational product


No related HPO nodes (Using clinical trials)